Steatohepatitis/Metabolic Liver Disease News

The FDA granted fast track designation to efinopegdutide for the treatment of nonalcoholic steatohepatitis, according to a manufacturer’s press release.

Healio will present its sixth annual Disruptive Innovators Awards for gastroenterology and hepatology this fall.

The Global Liver Institute has marked June 8 as International NASH Day, part of a public education campaign to raise awareness and urgency about fatty liver disease and its advanced form, nonalcoholic steatohepatitis.

Patients with nonalcoholic steatohepatitis experienced similar mental and work-related impairment as patients with type 2 diabetes mellitus but worse physical status, daily activities impairment and more health care resource use.

Intercept Pharmaceuticals saw a 16% drop in its stock value after an FDA advisory committee declined to approve obeticholic acid in pre-cirrhotic patients with liver fibrosis due to nonalcoholic steatohepatitis.

An FDA advisory committee voted against approval for obeticholic acid in pre-cirrhotic patients with liver fibrosis due to nonalcoholic steatohepatitis, citing “concerning” benefit-risk profile.

CHICAGO — Hospital admissions for alcohol-related cirrhosis jumped from March 2020 to March 2021, with associated increases in costs and mortality, according to study results presented at Digestive Disease Week.

CHICAGO — Patients with nonalcoholic fatty liver disease had worse COVID-19-related outcomes compared with infected individuals without NAFLD, according to data presented at Digestive Disease Week.

Bariatric surgery was linked to a decreased risk for major adverse cardiovascular events and all-cause mortality among patients with nonalcoholic fatty liver disease and obesity, according to results in JAMA Network Open.

The prevalence of nonalcoholic fatty liver disease was 14% among pregnant women screened during early pregnancy, with fewer than 5% receiving prior evaluation for NAFLD, according to research in Clinical Gastroenterology and Hepatology.